Reprocell (Biopta)

Reprocell (Biopta) isA global CRO with strengths in non-clinical evaluation using fresh human tissuesIt is. In addition to contract testing for efficacy, safety, ADME, etc., we also support ex vivo evaluation using patient-derived tissues.

Features of Reprocell's (Biopta) non-clinical contract testing services

Evaluate candidate compounds using fresh human tissue

The major feature of Reprocell (Biopta) isTest systems utilizing fresh human tissues, including those of patient originIt enables ex vivo evaluation of drug efficacy and safety across a wide range of tissues, including IBD, skin diseases, respiratory, and cardiovascular systems. Because human responses, which are difficult to capture with animal models alone, can be confirmed from the early stages of drug discovery, it can be utilized for Go/No-Go decisions on candidate compounds and decisions on transitioning to clinical trials. We also have a track record of being involved in the evaluation of over 1,000 new drug candidates since 2002.

Human tissue testing compliant with GLP

The company offersCRO GLP-certified for testing using fresh human tissueIt also supports evaluations based on ICH S7A in safety pharmacology, which can be conducted as GLP studies when necessary. In addition, comparative studies across animal species are available, making it possible to examine to what extent data obtained in animals can be replicated in humans. Because human tissue is handled, an organizational framework for tissue procurement is in place, including ethical review and informed consent.

Efficacy and ADME evaluation utilizing human tissue

In ADME/DMPK,Evaluation of permeability and metabolism in human gastrointestinal tissue using the Ussing chamberIt supports applications such as these. A key feature is the ability to evaluate while maintaining the enzymes and transporters inherent to human tissue, which are difficult to reproduce in conventional cell lines or animal tissues. Furthermore, it supports drug efficacy evaluation using patient-derived tissues, iPSC-derived models, and 3D tissue models. It also accommodates GLP studies intended for submission to regulatory authorities.

An example of a disease model owned by Reprocell (Biopta)

At Reprocell (Biopta),inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's diseaseWe offer human tissue models targeting . Using patient-derived intestinal tissue, we can evaluate the effects of candidate compounds on inflammatory responses and intestinal permeability. We also offer human tissue assays targeting diseases such as psoriasis, atopic dermatitis, COPD, and asthma.

Non-clinical study cases of Reprocell (Biopta)

Evaluate the safety of nNOS inhibitors in human resistance vessels

At Reprocell (Biopta),Vascular safety of selective nNOS inhibitorsThis has been investigated using fresh human subcutaneous resistance vessels. The presence or absence of human-specific vasoconstrictive risks and side effects, which are difficult to predict in animal models, is directly verified using human tissue. It is utilized as a method to reduce cardiovascular safety risks during the preclinical stage before proceeding to clinical trials.

Corporate Information of Reprocell (Biopta)